Article

Drug-induced nephrotoxicity caused by amphotericin B lipid complex and liposomal amphotericin B: a review and meta-analysis.

Immunology Research Program, Department of Infectious Diseases, Infection Control and Employee Health, The Anderson Cancer Center, Houston, Texas 77030, USA.
Medicine (Impact Factor: 4.87). 07/2010; 89(4):236-44. DOI: 10.1097/MD.0b013e3181e9441b
Source: PubMed

ABSTRACT Lipid preparations of amphotericin B, commonly used to treat fungal infections, have been demonstrated to have reduced nephrotoxicity compared to conventional amphotericin B. However, to our knowledge, a comprehensive comparison of nephrotoxicity induced by different lipid preparations of amphotericin B has not been performed. We conducted a meta-analysis to evaluate nephrotoxicity associated with amphotericin B lipid complex (ABLC) and liposomal amphotericin B (L-AmB). We searched the PubMed MEDLINE database and abstracts presented at key scientific meetings, and identified 11 studies reported between 1995 and 2008 that compared nephrotoxicity resulting from the use of these agents. Eight of the 11 studies were included in the meta-analysis. The Cochran-Mantel-Haenszel test was used to determine odds ratio (OR) and relative risk (RR), and the Breslow-Day test was used to analyze homogeneity of ORs across different studies. Analysis of all 8 studies (n = 1160) included in the meta-analysis showed an increased probability of nephrotoxicity in patients treated with ABLC versus L-AmB (OR, 1.75; RR, 1.55), but there was a significant lack of homogeneity across these studies (p < 0.001). After excluding the study by Wingard et al, the probability of experiencing nephrotoxicity was more similar between the 2 AmB lipid preparations (OR, 1.31; RR, 1.24; n = 916), particularly when the analysis included only the salvage patient population reported by Hachem et al (OR, 1.12; RR, 1.09; n = 839); the 7 remaining studies were more homogenous by Breslow-Day test (p = 0.054). Our results suggest that nephrotoxicity is generally similar for ABLC and L-AmB in patients receiving antifungal therapy and prophylaxis.

Download full-text

Full-text

Available from: Amar Safdar, Jul 28, 2015
0 Followers
 · 
287 Views
  • Source
    • "Amphotericin B is generally considered primary line of defence to tackle infections by Candida species and is often given in combination with more efficacious and less toxic systemic azole antifungal drugs such as fluconazole, miconazole, ketoconazole etc. However, amphotericin B overdose can be nephro and hepatotoxic (Safdar et al. 2010) and indiscriminate use of azole drug such as fluconazole can result in its intrinsic tolerance among C. albicans and non-albicans Candida species (Sanglard et al. 2003). Therefore, resistance to the azole antifungal drugs against Candida species has become predictable over a period of time which can be attributed to its fungistatic rather than the fungicidal nature in general (Vandenbosch et al. 2010). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Patil S, Maknikar P, Wankhade S, Ukesh C, Rai M. 2015. Antifungal effect of cumin essential oil alone and in combination with antifungal drugs. Nusantara Bioscience 7: 55-59. We report evaluation of antifungal activity of cumin seed oil and its pharmacological interactions when used in combination with some of the widely used conventional antifungal drugs using CLSI broth microdilution, agar disc diffusion and checkerboard microtitre assay against Candida. The essential oil was obtained from cumin seeds using hydrodistillation technique and was later evaluated for the presence of major chemical constituents present in it using gas chromatography and mass spectrometry (GC-MS) assay. The GC-MS assay revealed the abundance of γ-terpinene (35.42%) followed by p-cymene (30.72%). The agar disc diffusion assay demonstrated highly potent antifungal effect against Candida species. Moreover, the combination of cumin essential oil (CEO) with conventional antifungal drugs was found to reduce the individual MIC of antifungal drug suggesting the occurrence of synergistic interactions. Therefore, the therapy involving combinations of CEO and conventional antifungal drugs can be used for reducing the toxicity induced by antifungal drugs and at the same time enhancing their antifungal efficacy in controlling the infections caused due to Candida species.
  • [Show abstract] [Hide abstract]
    ABSTRACT: We retrospectively evaluated the rate of renal dysfunction during treatment with liposomal amphotericin B (L-AmB) (3–4 mg/kg, for 7–10 days) in nine consecutive patients with visceral leishmaniasis (VL). During the first week of treatment, 5 patients (56%) experienced transient deterioration of renal function, with a rise in serum creatinine to 1.27–2.44 times the baseline level, and a parallel elevation of uric acid levels without other metabolic or electrolyte disturbances. Serum renal function parameters were restored to normal levels after the completion of therapy, on day 21. These 5 patients had presented with prolonged fever and/or significant spleen enlargement, reflecting high parasite load. This observation suggests that treatment of VL with intermittent L-AmB causes a subclinical tumor lysis-like syndrome, especially in patients with high parasite load.
    Central European Journal of Medicine 06/2012; 7(3). DOI:10.2478/s11536-011-0147-5 · 0.21 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The technical feasibility of a converter without a wet electrolytic capacitor is demonstrated. The authors set out the actions undertaken to ensure that chemical capacitors in DC-DC converters are correctly used. They give the progression of study and realization, on the basis of a defined specification, of a 100 W high-frequency DC-DC converter, designed without a wet electrolytic capacitor. The different structures of resonant converters are analyzed to accept a forward zero voltage switching multiresonance converter working in a variable frequency between 800 kHz and 1.2 MHz. This converter allows and imposes the use of capacitors whose characteristics are described
    Telecommunications Energy Conference, 1991. INTELEC '91., 13th International; 12/1991
Show more